School of Medicine
Showing 381-390 of 856 Results
-
Cynthia Kapphahn
Clinical Professor, Pediatrics - Adolescent Medicine
Current Research and Scholarly InterestsAccess to health care services for adolescents.
Confidentiality.
Mental Health Financing.
Eating disorders. -
Siva Kasinathan
Instructor, Pediatrics - Rheumatology
BioSiva Kasinathan, MD, PhD is a physician-scientist and Instructor of Pediatric Rheumatology at the Stanford University School of Medicine and Lucile Packard Children's Hospital. In addition to caring for children and young adults with rheumatic diseases in his clinical practice, Siva conducts research to advance the understanding of mechanisms of autoimmunity and autoinflammation.
Siva holds an MD and PhD in Molecular and Cell Biology from the University of Washington, where he developed several high-throughput methods for epigenome profiling and contributed new insights in chromatin biology and gene regulation. During his clinical training in pediatrics and rheumatology at Stanford, Siva pioneered approaches for single-molecule analysis of genetic variation, DNA methylation, and chromatin structure, and established a longitudinal rheumatic disease cohort and biorepository.
Siva’s current research bridges genomics and immunology with a focus on developing and applying sensitive technologies to unravel the genetic and molecular underpinnings of lupus, arthritis, and other disorders of immune regulation. As a physician-scientist, Siva is committed to translating fundamental discoveries into precision therapies and biomarkers to improve outcomes for patients with immune-mediated diseases. -
Mark A. Kay, M.D., Ph.D.
Dennis Farrey Family Professor of Pediatrics, and Professor of Genetics
Current Research and Scholarly InterestsMark A. Kay, M.D., Ph.D. Director of the Program in Human Gene Therapy and Professor in the Departments of Pediatrics and Genetics. Respected worldwide for his work in gene therapy for hemophilia, Dr. Kay and his laboratory focus on establishing the scientific principles and developing the technologies needed for achieving persistent and therapeutic levels of gene expression in vivo. The major disease models are hemophilia, hepatitis C, and hepatitis B viral infections.
